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Abstract
Rare variants are thought to contribute to the genetics of inflammatory bowel disease (IBD), which is more common amongst 
the Ashkenazi Jewish (AJ) population. A family-based approach using exome sequencing of AJ individuals with IBD was 
employed with a view to identify novel rare genetic variants for this disease. Exome sequencing was performed on 960 Jew-
ish individuals including 513 from 199 multiplex families with up to eight cases. Rare, damaging variants in loci prioritized 
by linkage analysis and those shared by multiple affected individuals within the same family were identified. Independent 
evidence of association of each variant with disease was assessed. A number of candidate variants were identified, including 
in genes involved in the immune system. The ability to achieve statistical significance in independent case/control replica-
tion data was limited by power and was only achieved for variants in the well-established Crohn’s disease gene, NOD2. This 
work demonstrates the challenges of identifying disease-associated rare damaging variants from exome data, even amongst a 
favorable cohort of familial cases from a genetic isolate. Further research of the prioritized rare candidate variants is required 
to confirm their association with the disease.
Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are the 
two major forms of the inflammatory bowel diseases 
(IBD), a heterogeneous group of chronic and debilitating 
disorders involving inflammation of the gastrointestinal 
tract. The etiology of IBD involves an aberrant immune 
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response to commensal microflora in genetically suscep-
tible individuals (Malik 2015; Segal 2016). A positive 
family history remains the strongest risk factor for IBD, 
evidenced by epidemiological and genetic studies. The 
first gene associated with CD was NOD2 (Hugot et al. 
2001; Ogura et al. 2001). To date, genome-wide associa-
tion studies (GWAS) have identified over 240 risk loci for 
IBD (Anderson et al. 2011; Barrett et al. 2008; Franke 
et al. 2010; Jostins et al. 2012; Liu et al. 2015; Mirkov 
et al. 2017; de Lange et al. 2017). While the identified risk 
loci and underlying genetic associations have informed our 
understanding of the etiopathogenesis of IBD, the vari-
ance explained by these risk loci does not account for the 
estimated heritability of the disease.
Missing heritability is posited to be found in rare, high-
impact coding variants (Manolio et al. 2009). Such variants 
are difficult to identify in population-based exome sequenc-
ing studies due to limited power and the high baseline rate 
of rare, neutral variants (Zuk et al. 2014; Kosmicki et al. 
2016). In the context of IBD, studying the Ashkenazi Jew-
ish (AJ) population has the potential to facilitate rare variant 
identification because this population has a relatively high 
prevalence of IBD, at least fourfold that of non-Jewish Euro-
peans (Calkins and Mendeloff 1986; Odes et al. 1989; May-
berry et al. 1986; Roth et al. 1989; Bernstein et al. 2006). 
Furthermore, the AJs are a genetically isolated population 
(Carmi et al. 2014), characterized by repeated bottlenecks, 
expansions and endogamy with a consequential reduction in 
genetic heterogeneity (Ostrer 2001). Additional advantage 
can be gained by studying cases which are familial (Zielinski 
et al. 2012) or of an extreme phenotype, e.g., early onset 
cases (Uhlig and Schwerd 2016) as they are thought to be 
enriched for functional causal variants with stronger effects.
The increased incidence of CD amongst AJs has been 
genetically interrogated through GWAS (Kenny et al. 2012), 
which highlighted five novel CD-associated loci, and more 
recently by the analysis of exome sequence data from 
1855 AJ CD cases and 3044 AJ non-IBD controls (Rivas 
et al. 2018). AJ enriched CD risk alleles were observed in 
the well-established CD risk gene NOD2 and in the gene 
LRRK2. Furthermore, AJ CD cases and controls were found 
to have a greater CD polygenic risk score (incorporating 
124 CD risk alleles but not those in NOD2 or LRRK2) com-
pared with non-Jewish European individuals. The authors 
conclude the presence of a coordinated selection for both 
rare and common CD risk alleles in the AJ population (Rivas 
et al. 2018).
We recently demonstrated the utility of an AJ family-
based approach for identifying possible causal rare variants 
for IBD (Levine et al. 2016) through the study of the two 
largest AJ multiplex families described to date (54 and 26 
CD cases, respectively). A novel frameshift mutation in 
CSF2RB was identified which replicated in an independent 
AJ case/control cohort and was shown to cause a loss of 
function in vitro (Chuang et al. 2016).
With a view to further delineating the genetics of IBD, 
and in particular, to search for high-impact rare variants, we 
performed whole exome sequencing on a newly established 
cohort of 960 Jewish individuals from 199 small to medium 
sized multiplex families with IBD and sporadic cases. We 
employed linkage analysis and the prioritization of rare vari-
ants shared by multiple affected individuals within the same 
family. Independent evidence of replication of the associa-
tion of each variant with IBD was assessed with correction 
for multiple testing. The well-established gene, NOD2, was 
prioritized along with a number of other candidates. Despite 
the theoretical advantages afforded by studying AJ families, 
the identification of rare variants for IBD proves challenging.
Methods
Ethics
As per previously (Levine et al. 2016), ethical research gov-
ernance approval was provided by the National Research 
Ethics Service London Surrey Borders Committee (10/
H0906/115) and the University College London Research 
Ethics Committee (6054/001). Written informed consent 
was obtained from all participants.
Cohort summary
A large cohort of AJ individuals with IBD were recruited, 
primarily in the United Kingdom, through advertisements, 
hospitals and primary care (Schiff et al. 2018). Additional 
family members were recruited through the probands. Par-
ticipants were interviewed by telephone to ascertain their 
Jewish ancestry, IBD phenotype, age of diagnosis and family 
history of IBD both in first-degree and more distant relatives. 
Written confirmation of each affected individual’s diagnosis 
was obtained from his or her doctor in the majority of cases. 
Saliva samples were collected by post and DNA was isolated 
according to standard procedures (Quinque et al. 2006).
Whole exome sequencing was performed on 960 individ-
uals comprising 513 cases from 199 multiplex IBD families, 
364 sporadic cases and 83 unaffected individuals (predomi-
nantly relatives of affected individuals). The familial cases 
consisted of 340 individuals with CD, 160 with UC and 
13 with an unknown or unclassified IBD subtype (IBD-U). 
The sporadic cases consisted of 205 individuals with CD, 
153 with UC and 6 with IBD-U. Pedigrees for the 26 largest 
families with at least four affected individuals (lfams) are 
shown in Fig. 1. The number of exome sequenced affected 
individuals with IBD or CD per family are shown in Sup-
plementary Table 1.
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Whole‑exome sequencing
Data generation
Indexed paired-end libraries were prepared using the BGI 59 
Exome Enrichment Kit (BGI, China) or the Agilent SureSe-
lect Exome v4 Kit (Agilent, USA), and 2 × 150 bp sequenc-
ing was performed by BGI or Macrogen (Macrogen, South 
Korea) on the Illumina HiSeq 2000 system (Illumina, USA). 
Two samples were sequenced by both platforms and variant 
calls were 99.8% concordant (Supplementary Fig. 1).
Read alignment and variant calling
Sequence read alignment and variant calling was performed 
alongside 4325 other exomes (UCLex) using an in-house 
next-generation sequencing analysis pipeline (Pontikos et al. 
2017). Reads were aligned to the human reference genome 
build 37/hg19 by Novoalign (version 3.02.08) and variants 
were called using the Genome Analysis Toolkit (GATK) 
(McKenna et al. 2010) according to best practices with local 
realignment around indels, followed by joint variant calling 
and variant quality score recalibration (VQSR) (DePristo 
et  al. 2011). VQSR uses machine learning to calculate 
quality scores for variants considering a number of quality 
parameters and employing a training set of highly validated 
variants as likely true positives. Further requirements for 
quality assurance included: genotyping quality (GQ) ≥ 30, 
reference/alternate read depth for heterozygote calls approxi-
mates to a 1:1 ratio (Chi-squared test p ≥ 0.001), alternate 
read depth for heterozygote and homozygote calls ≥ 3 and 
VQSR truth tranche ≤ 99.5% for SNPs and ≤ 99.0% for 
indels. In addition, variants were required to have a call rate 
≥ 0.75 and to approximate to Hardy Weinberg Equilibrium 
(HWE) (chi-squared test, p ≥ 5 × 10− 8).
Variant annotation and filtering
The variant effect predictor (VEP version 76) (McLaren 
et al. 2016) was used to annotate all variants for their 
predicted impact on Ensembl gene transcripts and their 
frequency in Ashkenazi Jewish (gnomAD-AJ) individu-
als (n = 4925) and non-Finnish European (gnomAD-
NFE) individuals (n = 55,860) from the gnomAD exome 
database (Lek et al. 2016) (http://gnoma d.broad insti tute.
org). Missense variants were annotated for their predicted 
deleteriousness according to CAROL (Lopes et al. 2012). 
Custom-made scripts were used to further annotate each 
variant with their CADD score (Kircher et al. 2014) and 
their frequency in a cohort of 500 non-IBD unrelated indi-
viduals from amongst the jointly processed UCLex sam-
ples that were most proximal to the sequenced AJs based 
on principal component analysis (UCLex-pAJ), as defined 
below. A variant was considered potentially pathogenic, 
and hence included, if it was a frameshift, start loss, stop 
gain, splice site acceptor/donor variant, or a missense vari-
ant which was predicted to be damaging by CAROL and 
had a CADD score ≥ 20. Variants were filtered based on 
their population frequency using all of gnomAD-AJ, gno-
mAD-NFE and UCLex-pAJ; variants were considered as 
Fig. 1  Pedigrees for the 26 largest families (lfams) with four or more 
exome sequenced affected individuals (WES). Affected individuals 
are indicated by filled symbols. Deceased individuals are indicated by 
a diagonal line. Phenotype (IBD, CD or UC) is shown. a Five fami-
lies with two or more exome sequenced unaffected individuals. b 21 
families with no exome sequenced unaffected individuals
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Fig. 1  (continued)
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either very rare (AF < 0.005), rare (AF < 0.05) or common 
(AF > 0.05). If the reference genome carried the minor 
allele, then genotypes and population allele frequencies 
were flipped.
Quality control
Sex
The ascertained sex of each sample was verified by the 
homozygosity rate of common variants on the non-pseudo-
autosomal regions of the X chromosome (Supplementary 
Fig. 2).
Relatedness
KING (Manichaikul et al. 2010) was used to calculate 
a kinship coefficient for each pair of samples based on 
common variants to identify duplicates and verify the 
ascertained family pedigrees. Kinship coefficients were 
mapped to relationships using default thresholds as fol-
lows: > 0.354 for duplicate samples/monozygotic twins, 
0.177–0.354 for first-degree relatives, 0.0884–0.177 for 
second-degree relatives, 0.0442–0.0884 for third-degree 
relatives, and < 0.0442 for unrelated. In addition, a set of 
unrelated cases and a set of unrelated non-IBD UCLex 
samples were identified for use in ancestry quality control. 
A subset of the latter (UCLex-pAJ) was used for vari-
ant prioritization and gene burden testing (see “Ancestry” 
section).
Ancestry
The ascertained ancestry of samples was examined using 
principal component analysis (PCA) (Supplementary Fig. 3) 
with the R package FactoMineR (Lê et al. 2008). PCs were 
calculated from 5409 common independent exome-wide 
SNPs (Purcell et al. 2014) in 4602 unrelated UCLex sam-
ples. These samples include 1092 individuals from the 1000 
Genomes Project (1000 Genomes Project Consortium et al. 
2015) and 582 unrelated individuals from our cohort (as 
defined above). The remaining individuals in our cohort 
were projected onto the calculated PCs.
A subset of the recruited subjects was genetically defined 
as being of AJ ancestry as follows. The 920 individuals of 
self-declared AJ ancestry (excluding 40 from the recruited 
subjects of Sephardi, Middle Eastern (Ostrer 2001) or mixed 
Jewish ancestry) were defined by the first five PCs, multi-
variate outliers were removed and a five-dimensional Gauss-
ian model fitted. The number of PCs and the confidence 
region used were varied and the false positive rate tested. A 
90% ellipsoid confidence region captured 878 AJ individu-
als with only 17 false positives: sixteen that self-declared 
as being of Sephardi or Middle Eastern Jewish ancestry 
and one non-Jewish individual. The Mahalanobis distance 
from each non-IBD UCLex sample to these now genetically 
defined AJs was calculated to identify the 500 most proximal 
ancestry-matched controls (UCLex-pAJ).
Analysis approach
The prioritization of candidate variants for IBD in AJ mul-
tiplex families was performed by employing two principal 
strategies. The first sought to identify variants present in 
affected individuals across multiple families. For this, link-
age analysis of all the families in the cohort was performed 
separately for the phenotypes of CD and IBD (encompass-
ing CD, UC and IBD-U). UC was not examined separately 
owing to the smaller number of families with this phenotype. 
Loci with suggestive evidence of linkage were prioritized 
(LOD ≥ 1.5) and variants within these loci that were shared 
by the families contributing to the linkage signal were iden-
tified. As variants present across multiple families were, by 
definition, not expected to be exceedingly rare in the popu-
lation, an allele frequency (AF) threshold of < 0.05 (5%) 
was employed. Independent evidence of association with 
IBD, CD or UC was assessed for in a replication cohort of 
unrelated AJ cases and controls. The second strategy sought 
to identify rarer variants across the whole exome that may 
only be found in a smaller subset of the families via a family-
based rare variant prioritization analysis. For this, an AF 
threshold of < 0.005 (0.5%) was employed. As previously, 
independent evidence of association with IBD, CD or UC 
was assessed. Statistical evidence of an enrichment of the 
variant with disease amongst all the sequenced affected 
individuals in the families was further examined by gene 
dropping. Replication of such rare variants was limited by 
restrictive power (Kosmicki et al. 2016).
Linkage analysis
The SNP map used for linkage was generated as follows. 
First, all common (AF > 0.05) SNPs were extracted, assigned 
a genetic map position from the Rutgers map (Matise et al. 
2007) and pruned for linkage disequilibrium (LD) (window 
size 50 SNPs, step size 5, r2 threshold 0.2) in UCLex-pAJ 
using PLINK (Purcell et al. 2007). The remaining SNPs 
were assigned an AF using gnomAD-AJ. In each 0.3 cen-
tiMorgan (cM) window, only the SNP with maximum het-
erozygosity was retained using the lowest minor allele fre-
quency (MAF) SNP to break ties. The resulting SNP map 
contained 5945 SNPs.
Only affected individuals within the families were 
considered. The pedigrees were trimmed to remove 
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non-informative individuals using the R package kinship2 
(Sinnwell et al. 2014) leaving 150 informative families for 
IBD and 88 for CD. A non-parametric linkage analysis was 
performed using MERLIN (Abecasis et al. 2002) employing 
NPL ALL which places additional weight on families with 
three or more affected individuals (Whittemore and Halpern 
1994). The maximum theoretical LOD scores for IBD and 
CD were 65.6 and 38.4, respectively. Genes partially or fully 
within a region with a log odds (LOD) score ≥ 1.5 were 
selected. Although not at genome-wide significance (Lander 
and Kruglyak 1995), such loci demonstrate suggestive evi-
dence of linkage and may harbor disease-related variants. 
The per-family LOD scores at these loci were computed. For 
each of the linkage prioritized genes, rare (AF < 0.05) dam-
aging variants seen in at least two affected family members 
in at least two separate families that were contributing to the 
linkage (with mean LOD > 0 across the region of interest) 
were identified.
Family‑based rare variant prioritization 
and segregation analysis
With a view to identifying potentially pathogenic vari-
ants enriched in one or more family with the disease, 26 
families with four or more CD or IBD (CD, UC and IBD-
U) sequenced affected individuals (lfams) were consid-
ered (Fig. 1). Variants that were very rare in the popula-
tion (AF < 0.005) and that were predicted to be damaging 
(as above) were included. A variant was retained if it was 
observed in at least 75% of the affected individuals in at least 
one family (CD or IBD separately).
The segregation of variants to unaffected individu-
als within five families with at least two sequenced unaf-
fected carrier siblings or offspring for either CD or IBD was 
examined (Fig. 1a). Potential obligate carriers (parents of 
affected individuals) were excluded. The probabilities of the 
genotypes observed in these unaffected individuals, condi-
tional on the observed genotypes in the affected individuals 
(assuming heterozygosity and only one carrier founder) were 
calculated. Variants observed in less than one-third of the 
unaffected individuals were prioritized.
Case/control association for replication
Variants prioritized from both loci identified by linkage anal-
ysis and the family-based rare variant and segregation analy-
ses were examined for evidence of association with IBD 
(n = 1867), CD (n = 1286) and UC (n = 544) as compared 
with controls (n = 3035–3616) in an independent cohort of 
genetically confirmed AJ individuals (Rivas et al. 2018). For 
each phenotype in this independent dataset (IBD, CD and 
UC), identity by descent filtering was employed to remove 
related samples, prioritizing the cases, resulting in a slightly 
different number of controls for each. Per variant quality 
control of these data was undertaken using gnomAD indica-
tors including call rate and random forest based filtering. No 
data were available for variants for which the alternate allele 
was seen in only one case or control. Given the cohort sizes 
for each phenotype and alpha (p value threshold after correc-
tion for multiple testing, see below), power calculations were 
performed for a range of population AFs and effect sizes via 
a simulation approach which sampled log odds ratios and 
applied Fisher’s exact test.
Gene dropping for replication
Gene dropping (MacCluer et al. 1986) was used to assess 
for an enrichment of variants prioritized from the family-
based rare variant analysis in additional families in the 
study cohort relative to the control population. In each fam-
ily, a genotype (number of copies of the alternate allele) 
was assigned to each founder using a Binomial distribu-
tion where the number of trials was two and the success 
probability in each trial was the control AF (maximum of 
gnomAD-AJ, gnomAD-NFE and UCLex-pAJ). If data were 
not available from gnomAD-AJ (exomes), the gnomAD AJ 
whole-genome dataset was utilized (n = 151). A depth-first 
traversal starting from each founder (one per spousal pair) 
was performed, and in the case of heterozygotes, a random 
number generator determined which parental allele was 
transmitted to each child. Thus, every individual in the fam-
ily was assigned a genotype. Having performed this gene 
dropping across all the families, an overall simulated AF 
was calculated amongst all the cases excluding those from 
the family in which the variant was initially identified. The 
whole process was repeated 100,000 times, thus producing 
100,000 simulated AFs. The probability of the variant being 
at a greater frequency in the family disease cohort relative to 
the simulated frequency under the null, and hence independ-
ent evidence of association with disease, was calculated.
Given the alpha value (p value threshold after correction 
for multiple testing, see below), power calculations were 
performed for CD and IBD for a range of population and 
cohort AFs as follows. First, cohort AFs were simulated 
using the population AF (n = 100,000), then the number of 
simulated frequencies less than the cohort frequency was 
modeled as a binomial distribution, and finally this binomial 
distribution was approximated to a normal distribution to 
extract power.
Correction for multiple testing
A Bonferroni threshold correcting for multiple testing was 
calculated based on the number of variants prioritized from 
both the linkage analysis (n = 11) and the family-based rare 
variant analysis (n = 413). For the former, three datasets 
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were examined (IBD, CD and UC case/control replication). 
For the latter, two additional CD and IBD gene dropping 
datasets were examined. Examining all 424 variants, there 
was a highly significant correlation (Spearman’s rank test) 
between the CD and IBD case/control replication p values 
(p = 3.7 × 10− 8) but not between CD and UC (p = 0.234) 
or UC and IBD (p = 0.094). Amongst the 413 variants for 
which gene dropping was performed, there was also a highly 
significant correlation between the CD and IBD p values 
(p < 2 × 10− 16). There was no significant correlation between 
the case/control replication and the gene dropping p values 
(p = 0.53 for IBD and p = 0.71 for CD). As a consequence 
of the observed significant correlations, the number of data-
sets examined for the purpose of calculating the Bonferroni 
threshold was defined as two from the case/control replica-
tion and one from the gene dropping. Thus, the total number 
of tests performed was considered 11 × 2 + 413 × 3 yielding 
a Bonferroni threshold of p < 3.97 × 10− 5.
Gene burden testing
Gene burden analysis was performed to test for a statisti-
cally significant excess burden of rare damaging variants 
on a gene by gene basis amongst cases relative to controls. 
The cases utilized were the unrelated genetically defined AJ 
individuals (330 for CD and 550 for IBD). The controls were 
drawn from the UCLex-pAJ subjects with a case–control 
ratio of one (hence for IBD, the next 50 most proximal con-
trols were added to UCLex-pAJ). For each gene, a combined 
multivariate and collapsing (CMC) test (Li and Leal 2008) 
was applied. Variants with AF < 0.01 in gnomAD-AJ were 
aggregated into one binary variable and variants with an 
AF > 0.01 and < 0.05 into another. If the variant was absent 
in the gnomAD-AJ population, then gnomAD-NFE or 
UCLex-pAJ frequencies were used. Only damaging variants 
were considered. The multivariate test was a log-likelihood 
ratio (LLR) test in which the null and alternative hypothesis 
models included covariates for the first five ancestry PCs. 
Given the observed inflation (Supplementary Fig. 4), these 
results were only used to provide supplementary data for 
prioritized variants.
Results
Linkage analysis
Non-parametric linkage analysis of IBD identified two loci 
achieving LOD ≥ 1.5 on chromosomes 9 and 13 (Supple-
mentary Fig. 5A) with maximum LOD scores of 1.741 and 
1.873, respectively. Linkage analysis of CD identified only 
one locus achieving LOD ≥ 1.5, on chromosome 16 with a 
maximum LOD score of 2.074 (Supplementary Fig. 5B). 
Supplementary Table 2         summarizes these linkage 
regions in terms of their genomic position and the genes they 
contain. Of note, NOD2 is within the chromosome 16 locus.
The distribution of previously described CD-associated 
NOD2 variants amongst the cohort is shown in Supplemen-
tary Table 3. The variant G908R (rs2066845) failed qual-
ity control owing to a poor call rate. All of the other well-
established NOD2 variants (Huang et al. 2017; Rivas et al. 
2018) were identified in at least one family and their AF 
in the unrelated CD cases approximated to that in both the 
independent AJ case/control dataset and the literature (e.g., 
L1007insC/rs2066847 was observed at an AF of 0.075 in 
CD cases compared with 0.072 in CD cases in the AJ case/
control dataset).
A total of 51 rare (AF < 0.05) damaging variants were 
observed in at least two individuals in at least one family 
in the genes within the linkage-defined loci. Of these, 30 
variants were seen in a family contributing to the linkage 
(per-family LOD > 0) and 11 were seen in at least two such 
families (Table 1 and Supplementary Table 4) representing 
all three of the linkage loci. Replication data in unrelated AJ 
cases and controls were available for all of these variants. 
Examining IBD, CD and UC and employing the Bonferroni 
threshold of p < 3.97 × 10− 5 (see “Methods”), three variants, 
all within the gene NOD2, were significantly associated with 
disease. One additional NOD2 variant approached the sig-
nificance threshold (p = 3.7 × 10− 4). Of the eight remaining 
variants, none achieved p < 0.05 with a positive odds ratio. 
Their population control AFs ranged from 0.04 down to 
0.004. At this AF range, OR of 1.7–3.6, 2.1–3.8 and 2.1–5.5 
would be required for 80% power to achieve significance at 
the Bonferroni threshold in IBD, CD or UC, respectively.
Examining the gene burden results for the eight prior-
itized unique genes in CD and IBD, only NOD2 in CD was 
significant at p < 0.05 with p = 7.7 × 10− 6.
Family‑based rare variant prioritization
Examining very rare (AF < 0.005) damaging variants that 
were observed in at least 75% of the affected individuals in 
26 families with four or more affected individuals (lfams) 
identified 413 variants (Supplementary Table  5). One 
variant was observed in two lfams, a missense in NLRP9 
(rs143301793). Of the 413 variants, 362 were seen in an 
lfam with IBD and 233 were seen in an lfam with CD (182 
in common). The IBD variants were identified in 24 families 
with a median of 11.5 per family and a range of 1–51. The 
CD variants were identified in 13 families with a median of 
12 per family and a range of 5–51.
Replication data in unrelated AJ cases and controls were 
available for 207 of the 413 variants; the remainder were 
absent owing to failure to pass quality control filtering or 
due to an alternate allele count of zero or one in the cases 
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and controls examined. As expected, these 207 variants were 
more common than those for which replication data were 
missing (mean UCLex-pAJ AF 9.4 × 10− 4 versus 2.9 × 10− 4, 
Wilcoxon p = 9 × 10− 11). Examining IBD, CD and UC and 
employing the Bonferroni threshold of p < 3.97 × 10− 5, no 
variants were associated with disease. The variant with the 
smallest p value was a missense variant in the gene DNAH3 
(rs140821281, p = 0.0016). The population AFs for these 
variants ranged from zero to 4.99 × 10− 3. At an AF range of 
4.99 × 10− 3 down to 9 × 10− 6 (the smallest non-zero value 
observed), OR of 3.3–20.5, 3.4–24.6 and 4.8–33.5 would be 
required for 80% power to achieve significance at the Bon-
ferroni threshold in IBD, CD or UC, respectively.
In the gene dropping data, which examines for an excess 
of the variant in the familial cohort with the index family 
removed, two variants achieved the Bonferroni thresh-
old. These were a missense variant in the gene ZNF366 
(S332R) and a splice donor variant in the gene MDGA1 
(rs202070332). They were each seen in affected individuals 
in one additional family within the cohort yielding maximum 
disease cohort AFs of approximately 0.0015, enriched from 
the population frequency (zero) at p < 1 × 10− 5 (100,000 
simulations). No case/control replication data were avail-
able for either of these variants owing to their rarity.
At an AF range of 4.99 × 10− 3 down to 9 × 10− 6, the 
extent to which the AF in the family cohort would have 
to exceed the population control AF for 80% power to 
achieve significance at the Bonferroni threshold would be 
0.005–0.0167 for IBD. Examining only CD cases in the fam-
ilies, the equivalent increase would have to be 0.006–0.0203.
The 233 and 362 variants seen in a CD or IBD lfam, 
respectively, were in 226 and 353 unique genes. Gene bur-
den results were available for 187 and 305 of these, respec-
tively. No gene achieved p < 1.4 × 10− 4 (correcting for 353 
genes).
Segregation analysis
Amongst five families each with two or more unaffected 
offspring or siblings of affected individuals, 68 variants were 
present in ≥ 75% of the cases (CD or IBD). Of these vari-
ants, nine were present in ≤ 1/3 of the relevant unaffected 
family members (Table 2) from four families. Pedigrees of 
these families showing the segregation of the prioritized 
variants are in Supplementary Fig. 6.
None of these four families had power to detect a signifi-
cant lack of transmission of variants to ≤ 1/3 of the unaf-
fected family members conditional on the observed geno-
types amongst the affected individuals at p < 0.05.
Replication data were available for six of these variants, 
none of which were significant at p < 0.05.  The minimum 
gene dropping p value achieved was p = 0.016 for a missense 
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variant in CYB561A3. The power to detect an association is 
as given above.
Discussion
In this study, we have searched for rare coding variants for 
IBD using whole exome sequencing. This is a challenging 
endeavor because of the complex and polygenic nature of 
genetic susceptibility to IBD, itself a heterogeneous pheno-
type. To help address this complexity, we studied familial 
cases from the AJ population which, due to its population 
history, may harbor a smaller number of pathogenic variants 
compared with an outbred population. This is the first time 
a familial AJ IBD cohort of this size has been subjected to 
exome sequencing.
To identify rare, damaging variants potentially implicated 
in the aetiopathogenesis of the disease, we employed linkage 
analysis and selected variants observed in multiple members 
of the same family. The resulting prioritized variants were 
assessed for statistical evidence of association with IBD 
in an independent AJ case/control cohort and using gene 
dropping simulations. Through this approach, variants in the 
genes NOD2, ZNF366 and MDGA1 achieved statistical sig-
nificance after correcting for multiple testing. ZNF366 is of 
particular interest as it is a dendritic cell-specific transcrip-
tion factor implicated in the regulation of IL10 (Søndergaard 
et al. 2018). A large number of additional very rare variants 
were identified as being enriched in familial cases but the 
replication cohort and gene dropping simulations lacked the 
power to confirm or refute an association given their low 
frequency. It is also relevant to note that the gene dropping 
significance relies heavily upon the observed control AF, 
the accuracy of which is limited by the sample size of the 
studied cohorts (Qiao et al. 2017) and furthermore that the 
observation of a second family sharing a very rare variant 
(such that the gene dropping is significant) could be con-
founded by cryptic relatedness.
Variants were further prioritized based on their lack of 
transmission to unaffected siblings and offspring; although 
of limited power to achieve statistical significance, this pro-
vided suggestive evidence. A number of these variants were 
of interest as the genes were either previously described in 
relation to IBD [such as THEMIS (Chabod et al. 2012)] or 
were involved in the regulation of the innate immune system 
which is of increasingly recognized importance in the patho-
genesis of IBD (Sewell et al. 2012; Smith et al. 2009). These 
genes include MCOLN2 (Cuajungco et al. 2016) and NLRP2 
(Bruey et al. 2004). Interestingly, we previously identified 
a different variant in NLRP2 in another large AJ CD family 
(Levine et al. 2016).
Even with the advantages afforded by our study design, 
focusing on an isolated population and multiplex families, 
the robust identification of rare, damaging candidate variants 
proved challenging. This is likely secondary to technical/
analytic deficiencies, and importantly, insufficient power. 
Given the AF thresholds imposed in our study, the num-
ber of variants prioritized and the size of the replication 
cohort, 80% power to achieve significance would only be 
observed for a variant with an OR exceeding 2 or 3.5 at the 
higher limit of population AFs for rare (AF < 0.05) and very 
rare (AF < 0.005) variants, respectively, with these numbers 
increasing substantially as the AF decreases towards zero. 
Considerably larger cohort sizes would be required to test 
for association at smaller effect sizes for such rare variants. 
Furthermore, when examining the lack of transmission of 
candidate variants to unaffected individuals within families, 
there was an insufficient number of meiosis and larger num-
bers of unaffected individuals within these families would 
be required.
Table 2  Very rare (< 0.005) variants prioritized in four large families with at least two sequenced unaffected offspring or siblings of affected 
individuals, where ≤ 1/3 of the unaffected individuals carry a variant seen in at least 75% of the affected individuals
Full results are shown in Supplementary Table 5
Variant chromosome and genome position (Build 37) of variant with the reference and alternative alleles, Effect HGVS protein alteration, Con-
trol AF maximum allele frequency of gnomAD-AJ, gnomAD-NFE and UCLex-pAJ, Affected proportion of the affected individuals in the family 
heterozygous for the variant, Unaffected proportion of the unaffected individuals in the family heterozygous for the variant.
Variant rsID Gene Consequence Effect Control AF Affected Unaffected
1_85462527_TG_T rs748190234 MCOLN2 Frameshift Q10X 2.42×10-3 5/5 1/5
2_197873690_C_A ANKRD44 Missense D656Y 0 6/8 1/3
6_128134406_C_G rs141905910 THEMIS Missense K460N 1.93×10-3 6/8 1/3
8_1581122_C_G DLGAP2 Missense R494G 0 6/8 1/3
19_55496518_A_C rs775798143 NLRP2 Missense S712R 7.11×10-4 6/8 1/3
9_139286443_G_A rs61731233 SNAPC4 Missense A309V 3.28×10-3 5/5 3/9
19_41056172_C_T rs145109616 SPTBN4 Missense A1538V 3.13×10-3 4/5 3/9
11_61120544_G_T rs201384498 CYB561A3 Missense P171H 2.71×10-3 4/5 0/2
11_66009061_G_C rs202231158 PACS1 Missense G865R 4.98×10-3 4/5 0/2
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The unequivocal identification of NOD2 not only con-
firms its undoubtedly strong association with CD in this 
population but more importantly, it validates the methods 
used. The results also suggest that further damaging exonic 
single nucleotide risk variants for IBD in AJ multiplex fami-
lies at AF > 0.01 and < 0.05 that are of comparable effect 
size to that of the NOD2 variants are unlikely to be present.
This study has not examined the role of known IBD-asso-
ciated common variants (AF > 0.05) (Mirkov et al. 2017) 
which are recognized to contribute substantially to the herit-
ability of the disease, including in families (Stittrich et al. 
2016). To fully evaluate the genetic architecture of IBD in 
this familial AJ cohort, such variants will need examination.
This study has demonstrated the challenges of identifying 
disease-associated rare damaging variants from exome data, 
even amongst a favorable cohort of familial cases from a 
genetic isolate. Further research of the prioritized rare can-
didate variants is required to test their association with the 
disease. A combination of environmental factors, common 
variants, and rare variants (some of which we may have 
identified) are likely to contribute to the familial aggrega-
tion of IBD in AJ families.
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